Category - Developments

Pivotal Therapeutics (CSE:PVO; OTC PINK:PVTTF) currently is unable to repay $7.7-million of convertible notes, which came due March 4, 2016, and at least one noteholder has advised the company that it intends to...

WMUR Channel 9 in Manchester, NH has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction...

Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers. The...

Closely-held NovellusDx of Israel has appointed Heiner Dreismann and Dr. Charles Woler to the board. “The appointment of Drs. Dreismann and Woler, both venerated leaders in the biotech and pharma industries, with strong...

The FDA has extended its action date to consider approval of a NDA for Probuphine for the maintenance treatment of opioid addiction by the standard period to May 27 from Feb. 27. Following the Psychopharmacologic...

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported revenue of $20-million for the final quarter of 2015, up 54% from $13-million in the year earlier quarter, and up 18% from the third quarter of 2015. Product...

The New York Times has published an article about addiction medicines that includes a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the...

Microbix Biosystems (TSX:MBX) expects a strong performance over the rest of the fiscal year based on indicated customer demand, leading the company to project record sales for the current fiscal year, ending Sept. 30...

Avivagen (TSX-V:VIV) has started a trial with UNAHCO at the University of the Philippines Los Banos to measure the benefits of OxC-beta livestock as a feed additive for broiler poultry. Trial design reflects a...

Fresenius Medical Care (FSE:FME; NYSE:FMS) has extended its exclusive licensing agreement with closely-held Interface Biologics for use of the Endexo technology in chronic dialysis systems to cover the acute dialysis...